Trinity Biotech
TRIB
79 hedge funds and large institutions have $220M invested in Trinity Biotech in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 22 increasing their positions, 32 reducing their positions, and 4 closing their positions.
6,000% more call options, than puts
Call options by funds: $61K | Put options by funds: $1K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15% more capital invested
Capital invested by funds: $191M → $220M (+$28.9M)
0% more funds holding
Funds holding: 79 → 79 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
31% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Breithorn Capital Management
New York
|
+$1.48M |
| 2 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$1.32M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.21M |
| 4 |
Millennium Management
New York
|
+$962K |
| 5 |
Renaissance Technologies
New York
|
+$933K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
-$4.23M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.78M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$1.06M |
| 4 |
EA
Emerald Acquisition
Seattle,
Washington
|
-$772K |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$581K |
TRIB Hedge Fund Activity: Q3 2016 in Review
79 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2016, worth a combined $220M — up 15% from $191M a quarter earlier.
Fund positioning in TRIB was balanced in Q3 2016: 4 funds opened new positions, 4 closed out, 22 added to existing stakes and 32 trimmed.
The largest buyer was Breithorn Capital Management, adding an estimated $1.48M. The largest seller was Royce & Associates, cutting an estimated $4.23M.
- 79 institutional investors held Trinity Biotech (TRIB) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $220M of Trinity Biotech stock for Q3 2016, up 15% quarter-over-quarter.
- 4 funds opened new Trinity Biotech positions in Q3 2016 and 4 closed out, a net change of 0 holders.
- The largest Trinity Biotech buyer in Q3 2016 was Breithorn Capital Management, an estimated $1.48M added.
- The largest Trinity Biotech seller in Q3 2016 was Royce & Associates, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2016.